About TennesseeLifeScience.com
TennesseeLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Tennessee's BioHistory
Why is there a biotechnology industry in Tennessee? Will the industry continue
to grow in Tennessee? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Tennessee BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Tennessee.
More TN BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- CryoLife announces first implant of combination aortic-mitral allograft heart valve CryoLife announced the first implantation of the combination aortic-mitral allograft heart valve in a patient at the Cleveland Clinic. The surgery was performed by Dr. Jose Navia, a cardiac surgeon with the Heart and Vascular Institute at the Cleveland Clinic.
CryoLife, Inc. May 12, 2008
- Lilly completes final phase of its Indianapolis Biotechnology Complex Eli Lilly and Company announced completion of the final phase of its $1 billion effort to further strengthen the company's biotechnology research and development capabilities.
Eli Lilly and Company May 12, 2008
- Stereotaxis' market leadership highlighted at Heart Rhythm 2008 Stereotaxis announced that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation.
Stereotaxis, Inc. May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
- AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
AstraZeneca May 08, 2008
More... | Submit News Release | National News
|